Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that regulate cell-matrix composition and are also involved in processing various bioactive molecules such as cell-surface receptors, chemokines, and cytokines. Our group recently reported that MMP-3, -8, and -9 are upregulated durin...
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that regulate cell-matrix composition and are also involved in processing various bioactive molecules such as cell-surface receptors, chemokines, and cytokines. Our group recently reported that MMP-3, -8, and -9 are upregulated during microglial activation and play a role as proinflammatory mediators (Lee et al., 2010, 2014). In particular, we demonstrated that MMP-8 has tumor necrosis factor alpha (TNF-${\alpha}$)-converting enzyme (TACE) activity by cleaving the prodomain of TNF-${\alpha}$ and that inhibition of MMP-8 inhibits TACE activity. The present study was undertaken to compare the effect of MMP-8 inhibitor (M8I) with those of inhibitors of other MMPs, such as MMP-3 (NNGH) or MMP-9 (M9I), in their regulation of TNF-${\alpha}$ activity. We found that the MMP inhibitors suppressed TNF-${\alpha}$ secretion from lipopolysaccharide (LPS)-stimulated BV2 microglial cells in an order of efficacy: M8I>NNGH>M9I. In addition, MMP inhibitors suppressed the activity of recombinant TACE protein in the same efficacy order as that of TNF-${\alpha}$ inhibition (M8I>NNGH>M9I), proving a direct correlation between TACE activity and TNF-${\alpha}$ secretion. A subsequent pro-TNF-${\alpha}$ cleavage assay revealed that both MMP-3 and MMP-9 cleave a prodomain of TNF-${\alpha}$, suggesting that MMP-3 and MMP-9 also have TACE activity. However, the number and position of cleavage sites varied between MMP-3, -8, and -9. Collectively, the concurrent inhibition of MMP and TACE by NNGH, M8I, or M9I may contribute to their strong anti-inflammatory and neuroprotective effects.
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that regulate cell-matrix composition and are also involved in processing various bioactive molecules such as cell-surface receptors, chemokines, and cytokines. Our group recently reported that MMP-3, -8, and -9 are upregulated during microglial activation and play a role as proinflammatory mediators (Lee et al., 2010, 2014). In particular, we demonstrated that MMP-8 has tumor necrosis factor alpha (TNF-${\alpha}$)-converting enzyme (TACE) activity by cleaving the prodomain of TNF-${\alpha}$ and that inhibition of MMP-8 inhibits TACE activity. The present study was undertaken to compare the effect of MMP-8 inhibitor (M8I) with those of inhibitors of other MMPs, such as MMP-3 (NNGH) or MMP-9 (M9I), in their regulation of TNF-${\alpha}$ activity. We found that the MMP inhibitors suppressed TNF-${\alpha}$ secretion from lipopolysaccharide (LPS)-stimulated BV2 microglial cells in an order of efficacy: M8I>NNGH>M9I. In addition, MMP inhibitors suppressed the activity of recombinant TACE protein in the same efficacy order as that of TNF-${\alpha}$ inhibition (M8I>NNGH>M9I), proving a direct correlation between TACE activity and TNF-${\alpha}$ secretion. A subsequent pro-TNF-${\alpha}$ cleavage assay revealed that both MMP-3 and MMP-9 cleave a prodomain of TNF-${\alpha}$, suggesting that MMP-3 and MMP-9 also have TACE activity. However, the number and position of cleavage sites varied between MMP-3, -8, and -9. Collectively, the concurrent inhibition of MMP and TACE by NNGH, M8I, or M9I may contribute to their strong anti-inflammatory and neuroprotective effects.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
대상 데이터
LPS (Escherichia coli serotype 055:B5) was obtained from Sigma-Aldrich (St Louis, MO, USA). MMP-3 inhibitor (NNGH),MMP-8 inhibitor (M8I), and MMP-9 inhibitor (M9I) were purchased from Calbiochem (La Jolla, CA, USA).
(A) Effect of MMP inhibitors (NNGH, M8I, M9I) and TAPI-0 on TACE enzymatic activity. Recombinant human (rh) TACE protein (250 ng) was premixed with NNGH, M8I, M9I, or TAPI-0. After 30 min, the fluorogenic TACE substrate was added to the mixture of TACE and inhibitor, and the fluorescence was measured as described in the Methods section.
데이터처리
The data are presented as means ± S.E.M., and statistical comparisons between groups were performed using one-way analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison test.
성능/효과
05, significantly different from TACE activity of rhTACE. (B) IC50 values of MMP inhibitors and TAPI-0 on TACE activity of rhTACE are summarized. (C) TACE activities of rhMMP-3, rhMMP-8, and rhMMP-9 protein (250 ng) were determined as described in the Methods section.
후속연구
Further studies are necessary to identify the structural-functional relationship regarding TNF-α /TACE inhibition by MMP inhibitors.
참고문헌 (26)
Aggarwal BB 2003 Signaling pathways of the TNF superfamily: a double-edged sword Nat Rev Immunol 3 745 756 12949498
Agrawal SM Lau L Yong VW 2008 MMPs in the central nervous system: where the good guys go bad Semin Cell Dev Biol 19 42 51 17646116
Asai M Hattori C Szabó B Sasagawa N Maruyama K Tanuma S Ishiura S 2003 Putative function of ADAM9, ADAM10, and ADAM17 as APP α-secretase Biochem Biophys Res Commun 301 231 235 12535668
Bahia MS Silakari O 2010 Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders Chem Biol Drug Des 75 415 443 20486929
Black RA Rauch CT Kozlosky CJ Peschon JJ Slack JL Wolfson MF Castner BJ Stocking KL Reddy P Srinivasan S Nelson N Boiani N Schooley KA Gerhart M Davis R Fitzner JN Johnson RS Paxton RJ March CJ Cerretti DP 1997 A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 729 733 9034190
Bocchini V Mazzolla R Barluzzi R Blasi E Sick P Kettenmann H 1992 An immortalized cell line expresses properties of activated microglial cells J Neurosci Res 31 616 621 1578513
Candelario-Jalil E Yang Y Rosenberg GA 2009 Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia Neuroscience 158 983 994 18621108
Dev R Srivastava PK Iyer JP Dastidar SG Ray A 2010 Therapeutic potential of matrix metalloprotease inhibitors in neuropathic pain Expert Opin. Investig. Drugs 19 455 468
Gearing AJ Beckett P Christodoulou M Churchill M Clements JM Crimmin M Davidson AH Drummond AH Galloway WA Gilbert R Gordon JL Leber TM Mangan M Miller K Nayee P Owen K Patel S Thomasv W Wells G Wood LM Woolley K 1995 Matrix metalloproteinases and processing of pro-TNF-alpha J Leukoc Biol 57 774 777 7759957
Hu J Van den Steen PE Sang QXA Opdenakker G 2007 Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases Nat Rev Drug Dicsov 6 480 498
Javaid MA Abdallah MN Ahmed AS Sheikh Z 2013 Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview Acta Neurol Belg 113 381 390 24002649
Lee EJ Woo MS Moon PG Baek MC Choi IY Kim WK Junn E Kim HS 2010 α-Synuclein activates microglia by inducing the expressions of matrix metalloproteases and the subsequent activation of protease-activated receptor-1 J Immunol 185 615 623 20511551
Lee EJ Han JE Woo MS Shin JA Park EM Kang JL Moon PG Baek MC Son WS Ko YT Choi JW Kim HS 2014 Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-α activation J Immunol 193 2384 2393 25049354
Li NG Tang YP Duan JA Shi ZH 2014 Matrix metalloproteinase inhibitors: a patent review (2011 – 2013) Expert Opin Ther Pat 24 1039 1052 25098768
Mayhan WG 2002 Cellular mechanisms by which tumor necrosis factor-α produces disruption of the blood-brain barrier Brain Res 927 144 152 11821008
McCoy M Tansey MG 2008 TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease J. Neuroinflammation 5 45 18925972
Minond D Cudic M Bionda N Giulianotti M Maida L Houghten RA Fields GB 2012 Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates J Biol Chem 287 36473 36487 22927435
Morancho A Rosell A García-Bonilla L Montaner J 2010 Matrix metalloproteinase and stroke infarct size: role for anti-inflammatory treatment Ann N Y Acad Sci 1207 123 133 20955435
Moss ML Jin SL Milla ME Bickett DM Burkhart W Carter HL Chen WJ Clay WC Didsbury JR Hassler D Hoffman CR Kost TA Lambert MH Leesnitzer MA McCauley P McGeehan G Mitchell J Moyer M Pahel G Rocque W Overton LK Schoenen F Seaton T Su JL Becherer JD 1997 Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha Nature 385 733 736 9034191
Moss ML Sklair-Tavron L Nudelman R 2008 Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis Nat Clin Pract Rheumatol 4 300 309 18414459
Tian L Ma L Kaarela T Li Z 2012 Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases J. Neuroinflammation 9 155 22747919
Verma RP Hansch C 2007 Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs Bioorg Med Chem 15 2223 2268 17275314
Verslegers M Lemmens K Hove IV Moons L 2013 Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system Prog Neurobiol 105 60 78 23567503
Woo MS Park JS Choi IY Kim WK Kim HS 2008 Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia J. Neurochem 106 770 780 18419763
※ AI-Helper는 부적절한 답변을 할 수 있습니다.